Pediatric patient inflammatory bowel disease

Kader, H.A., et al. (2005) Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-betal, and IL-12p40 levels in Crohn s disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 100, 414-23. 

BQrschner BS. Safety of azathioprine and 6-mercaptopur-ine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998 115(4) 813-21. 

Inflammatory bowel disease (Crohn s disease and ulcerative colitis) occurs among all age groups but has peaks of incidence in the second and fourth decade of life. Currently, corticosteroid therapy is the most effective treatment for moderate to severe cases of IBD. Ocular pathology in the setting of IBD may be related to inflammation of the gastrointestinal tract or secondary to corticosteroid treatment. The two major ocular side effects of systemic corticosteroid therapy are posterior subcapsular cataract (PSC) and raised intraocular pressure (lOP). Recently, we reported that PSC was detected in 12 of 58 (20.7%) corticosteroid-treated pediatric IBD patients and that 21 patients of the same population (36.2%) had raised lOP. Because pediatric IBD patients continue corticosteroid therapy into adulthood, we analyzed the prevalence of PSC and raised lOP in a series of adult IBD patients. 

Karrison, and J.T. Ernest, Corticosteroid treatment for inflammatory bowel disease in pediatric patients increases intraocular pressure, Gastroenter. 102 1957(1992). 

---